Unknown

Dataset Information

0

Reclassification of RAS/BRAF allele mutations predicts the survival benefit of triplet chemotherapy in metastatic colorectal cancer.


ABSTRACT:

Background

Different RAS/BRAF allele mutations imply distinct biological properties in various solid tumors. Recently, several studies have focused on the predictive and prognostic roles of various RAS/BRAF allele mutations in colorectal cancer (CRC) but the results remain controversial.

Methods

Between March 2017 and September 2022, the patients diagnosed as stages I-IV CRC with detailed medical records including next-generation sequencing (NGS) data and clinicopathological follow-up information available at our center were enrolled. Survival data were estimated using the Kaplan-Meier method, and the difference was tested in a log-rank test. Multivariate tests were carried out using Cox models.

Results

A total of 1029 CRC patients were included, and the incidence of RAS/BRAF mutation was 58.4%. The hypermutated cohort was defined as patients with microsatellite instability-H or POLE/D mutation. In the non-hypermutational cohort, only KRAS G13D mutation was associated with a higher incidence and inferior disease-free survival in patients with stage I-III CRC. In the cohort of patients with non-hypermutated metastatic colorectal cancer (mCRC), we assessed the risk of various RAS/BRAF allele mutations and subsequently reclassified patients into four groups based on first-line median progression-free survival: wild type (group 1), low-risk RAS/BRAF mutation (group 2, RAS/BRAF mutations other than KRAS G13D/G12V/G12C or BRAF V600E), high-risk RAS mutation (group 3, KRAS G13D/G12V/G12C), and BRAF V600E mutation (group 4). mCRC patients with high-risk RAS mutation could significantly benefit from intensive triplet chemotherapy (hazard ratio, 2.54; 95% confidence interval, 1.36-5.12; p = 0.0091).

Conclusion

In the non-hypermutated CRC cohort, the prognostic risk of various RAS/BRAF allele mutations varied between local and metastatic CRC. KRAS G13D mutation tended to be the only prognostic marker for stages I-III CRC; however, KRAS G13D/G12V/G12C mutations collectively defined a high-risk subgroup of mCRC patients with poor prognosis, who would benefit from intensive triplet chemotherapy.

SUBMITTER: Zhang X 

PROVIDER: S-EPMC10826380 | biostudies-literature | 2024

REPOSITORIES: biostudies-literature

altmetric image

Publications

Reclassification of <i>RAS/BRAF</i> allele mutations predicts the survival benefit of triplet chemotherapy in metastatic colorectal cancer.

Zhang Xiang X   Ma Haizhong H   He Yinjun Y   He Wenguang W   Chen Nan N   Li Yandong Y   Zhong Weixiang W   Wu Guosheng G   Zhou Xile X   Hua Hanju H   Ye Feng F   Cai Hui H   Jiang Weiqin W  

Therapeutic advances in medical oncology 20240128


<h4>Background</h4>Different <i>RAS/BRAF</i> allele mutations imply distinct biological properties in various solid tumors. Recently, several studies have focused on the predictive and prognostic roles of various <i>RAS/BRAF</i> allele mutations in colorectal cancer (CRC) but the results remain controversial.<h4>Methods</h4>Between March 2017 and September 2022, the patients diagnosed as stages I-IV CRC with detailed medical records including next-generation sequencing (NGS) data and clinicopath  ...[more]

Similar Datasets

| S-EPMC7346377 | biostudies-literature
| S-EPMC5863340 | biostudies-literature
| S-EPMC6702298 | biostudies-literature
| S-EPMC4580381 | biostudies-literature
| S-EPMC8433607 | biostudies-literature
| S-EPMC6657223 | biostudies-literature
| S-EPMC4580391 | biostudies-literature
| S-EPMC6982651 | biostudies-literature
| S-EPMC6380651 | biostudies-literature
| S-EPMC6717744 | biostudies-literature